Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04588727 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT04588727 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 103 participants.
The verdict
NCT04588727, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single intravenous (IV) ascending doses. Part B of this study is a randomized, single-blind, parallel group placebo-controlled study to assess the safety, tolerability and PD of a single IV administration of AZD3366 with concomitant loading doses followed by repeated maintenance dosing of ticagrelor and acetylsalicylic acid (ASA).
Interventions
- DRUG Placebo
- DRUG Ticagrelor
- DRUG acetylsalicylic acid (ASA)
- DRUG AZD3366
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04588727
The ClinicalTrials.gov registry entry for NCT04588727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04588727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04588727 about?
NCT04588727 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects". Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single intravenous (IV) ascending doses. Part B of this study is a randomized, single...
What is the current status of trial NCT04588727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2020-10-15. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT04588727?
The interventions under investigation include: Placebo (DRUG), Ticagrelor (DRUG), acetylsalicylic acid (ASA) (DRUG), AZD3366 (DRUG).
Who is sponsoring clinical trial NCT04588727?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.